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LABORATORY INVESTIGATION
A role for oxygen free radicals in aminonucleoside nephrosis
JONATHAN R. DIAMOND, JOSEPH V. BONVENTRE, and MORRIS J. KARNOVSKY
Department of Pathology, Harvard Medical School, and Renal Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
A role for oxygen free radicals in aminonucleoside nephrosis. The
cellular processes responsible for the proteinuria induced by the
aminonucleoside of puromycin (PA) remain inadequately defined. Hy-
poxanthine is both a metabolic breakdown product of PA as well as a
substrate for xanthine oxidase, which catalyzes its enzymatic conver-
sion to xanthine and uric acid, yielding the superoxide anion in the
process. We examined whether oxygen free radical production contrib-
utes to the development of proteinuria in this model. Seven groups of
male Sprague-Dawley rats were studied. Proteinuria was quantitated
and histology examined 7 days after rats were treated with PA intrave-
nously over 5 mm. PA-treated animals received either saline, dimethyl
sulfoxide, superoxide dismutase, or catalase over 30 mm prior to and 30
mm following PA administration. Another group received allopurinol
over 4 hr prior to PA. The superoxide dismutase and allopurinol
treatment groups had a significant suppression of urinary protein
excretion compared to the PA control group. There were also less
severe glomerular morphologic changes in the superoxide dismutase
group vs. the PA controls, which demonstrated a pathologic pattern
that included epithelial cell blebbing, segmental mesangial cell prolifer-
ation and matrix expansion, loss of glomerular capillary lumina, and
occasional adhesions between the glomerular tuft and Bowman's cap-
sule. The allopurinol group exhibited normal glomerular morphology on
light microscopy, with the exception of occasional epithelial cell blebs.
All groups showed spreading of the epithelial cell cytoplasm along the
glomerular basement membrane with loss of foot processes, focal areas
of lifting of the epithelial cell from the glomerular basement membrane,
cytoplasmic vacuolization, and protein reabsorption droplets; however,
allopurinol-treated animals demonstrated these changes to a lesser
extent. The protective effects of superoxide dismutase and allopurinol
provide indirect evidence that oxygen free radicals generated by
xanthine oxidase are important mediators of PA-induced proteinuria.
Marked proteinuria and glomerular morphologic changes,
similar to those seen in minimal change disease in humans, are
observed in rats given a single intravenous injection of the
aminonucleoside of puromycin (PA) [1]. Studies by Hoyer et al
[2, 3] demonstrated that PA produces a rapid, direct biochem-
ical effect on the kidney, although the proteinuria does not
occur for several days following administration of the drug.
Ryan and Karnovsky [4] proposed that the early massive
proteinuria in this model was due to a glomerular epithelial cell
(GEC) lesion that resulted in loss of foot processes and appear-
ance of focal defects in the epithelial covering of the glomerular
basement membrane (GBM). The authors noted that protein-
uria increased to a maximum mean of 113 mg per 24 hr at 12
days and correlated with the persistence of a focal loss of an
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epithelial covering on the outside of the GBM [4]. By the fourth
week following PA administration, the level of protein excre-
tion and morphologic appearance of glomeruli were indistin-
guishable from those of control animals, suggesting spontane-
ous healing of the lesion [4]. Recently, Fishman and Karnovsky
[5] demonstrated, in vitro, the sensitivity of the GEC to PA, as
manifested by both morphologic and synthetic defects in tissue
culture. Other workers have identified both charge- and size-
selective defects in the glomerular barrier following administra-
tion of PA [6]. To date, there is a controversy as to whether
there is loss of anionic sites from the GBM [7, 8]. However, at
the level of the GEC, it has been shown that there is a reduction
in the surface charge of the GEC in PA-treated rats [71 and
subsequent studies have demonstrated defective glycosylation
of the glomerular sialoprotein, podocalyxin [9, 10], to account
for the charge-selective defect. Despite extensive study of this
model, the precise pathobiologic insult at the cellular level
responsible for the massive proteinuria remains unexplained.
The present investigation was undertaken to assess the role
of oxygen free radicals in this model of glomerular injury.
Hypoxanthine, an intermediate metabolite of PA [111, has been
shown to act as a substrate for oxygen free radical generation in
cellular systems where the enzyme xanthine oxidase is func-
tional [12]. In the feline intestine [12, 131 and hamster cheek
pouch [14], oxygen free radicals, derived from hypoxanthine
and xanthine oxidase, augmented vascular permeability to
macromolecules. In these preparations, oxygen free radical
scavengers [12, 13, 15], or allopurinol [12], a xanthine oxidase
inhibitor, significantly diminished macromolecular extravasation.
Our hypothesis was that the glomerular injury associated
with PA was mediated by oxygen free radical generation since
hypoxanthine, an intermediate metabolite of PA [11], can serve
as the substrate for superoxide anion production via the
xanthine oxidase system (Fig. I). To test this hypothesis, we
examined the efficacy of oxygen free radical scavengers and
xanthine oxidase inhibition to diminish the proteinuria of
aminonucleoside nephrosis in the rat.
Methods
Preparation of animals
Seven groups of male Sprague-Dawley rats (Charles River,
Wilmington, Massachusetts, USA) weighing 170 to 280 g were
studied. There were five animals in all groups, except for the
high-dose dimethyl suifoxide (DMSO) group which had eight.
Animals were anesthetized with an intraperitoneal injection of
sodium pentobarbital (30 mg/kg) and a tapered polyethylene
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Fig. 1. Metabolic degradation of the aminonucleoside of puromycin to
hypoxanthine with the proposed mechanism of oxygen free radical
formation via xanthine oxidase (Modified, in part, from Granger et a!
[131). Abbreviations: are 02, superoxide anion; SOD, superoxide
dismutase; H202, hydrogen peroxide; OHS, hydroxyl radical; DMSO,
dimethyl sulfoxide. Arrows with two crosses denote inhibition (a!-
lopurinol), scavenging function (DMSO), or catalyst of hydrogen per-
oxide removal (catalase).
catheter (PE 50) was placed into the right internal jugular vein.
Six of the seven groups received a single intravenous injection
of aminonucleoside of puromycin (5 mg/100 g body wt) over 5
mm via the jugular vein cannula. The seventh group received an
equal volume of 0.9 g/l00 ml sodium chloride. The PA-treated
animals received either superoxide dismutase (SOD, 15 mg/kg
body wt), catalase (CAT, 40 mg/kg body wt), dimethyl sulfoxide
(DMSO, 80 mg/kg or 4 g/kg body wt), or 0.9 gIlOO ml sodium
chloride over 30 mm prior to and 30 mm following PA admin-
istration via a second internal jugular vein cannula. Another
group received allopurinol (100 mg/kg body wt) over 4 hr prior
to PA. These dosage regimens were chosen based on both in
vivo and in vitro studies where they were shown to be protec-
tive against oxygen free radical-mediated augmentation of vas-
cular permeability [12—15]. All drugs were dissolved in 3 ml of
0.9 g/lOO ml sodium chloride with the exception of allopurinol,
which was initially dissolved in 1 ml of iN sodium hydroxide
and then diluted 1:100 with 5% dextrose and water. No appar-
ent acute toxic effects of drug infusion were noted except for
the appearance of hemoglobmnuria (detected by Hemastix,
Ames Company, Elkhart, Indiana, USA) at the end of the
high-dose DMSO infusion. The animals were allowed free
access to water and food. Seven days later the rats were placed
into metabolic cages and a 24-hr urine collection was obtained
for measurement of protein, osniolality, and osmolar clearance.
Total protein was quantitated by the Lowry method [16}. Serum
for creatinine and osmolality was obtained prior to sacrifice 8
days after PA administration. Urine and serum osmolality was
measured with a vapor pressure osmometer (Wescor, Logan,
Utah, USA).
Preparation for light and electron microscopy
Eight days after PA administration animals were anesthetized
with ether and the kidneys were perfused, in vivo, via an
infrarenal aortic cannula. The perfusate solution consisted of a
0.1 M cacodylate buffer containing 5% sucrose (pH 7.4) for 2 to
Catalase 3 mm followed by 2% glutaraldehyde in 0.1 M cacodylate buffer
for 1 to 2 mm. Both kidneys were removed and the cortices
were separated from the remainder of the kidneys and im-
mersed in 2% glutaraldehyde in cacodylate buffer for an addi-
tional 2 hr. After fixation, 1 to 2 mm cortical sections were
rinsed for 2 hr in 0.1 M cacodylate buffer with 5% sucrose (pH
7.4) and prepared for light and electron microscopy. Specimens
were post-fixed in 2% osmium tetroxide for 1 hr, dehydrated in
acetone, and embedded in Spun medium. Thick sections,
approximately 1 micron, were stained with 1% toluidine blue
and viewed with a Leitz photomicroscope. Thin sections (60 to
80 nM) were stained with 4% aqueous uranyl acetate and lead
citrate and examined with an AEI electron microscope.
Materials
The aminonucleoside of puromycin (PA), dimethyl sulfoxide
(DMSO), superoxide dismutase (SOD), catalase, and al-
lopunnol were obtained from Sigma Chemical Co. (St. Louis,
Missouri, USA).
Statistics
Significance of differences among groups was determined by
one-way analysis of variance. Comparison of means between
groups were performed using the F test of significance.
Results
Serum and urinaly parameters
Animals administered PA had a marked increase in 24-hr
protein excretion measured 7 days later (Table 1). Animals
receiving allopurinol or SOD prior to and subsequent to PA had
significantly less proteinuria. The group receiving the xanthine
oxidase inhibitor excreted 75.8 11.3 mg124 hr (P < 0.001) and
animals treated with SOD had 111 41.7 mg124 hr (P < 0,005)
compared to the PA control group, which excreted 363.8 84.2
mg/24 hr. In addition, 3 days after PA administration, al-
lopurinol-treated rats had urinary protein excretion rates that
were equivalent to normal rats of similar age and weight.
Animals that were treated with infusions of catalase, low- or
high-dose DMSO did not show any significant modification of
proteinuria compared with the group receiving PA alone.
As indicated in Table 1, all groups were comparable in body
wt and 24-hr urine volume. Serum creatinine, determined on
Day 8 following injection, was indistinguishable among groups
except for the high-dose DMSO group where serum creatinine
was significantly elevated. Except for the high-dose DMSO
group, there were no differences between the groups in the
glomerular filtration rate, as estimated by creatinine clearance.
The SOD pretreatment group had a significantly higher urine
osmolality when compared to all groups (P < 0.05). Although
not significantly different from the PA group, the mean urine
osmolality in the allopurinol group was approximately equal to
animals receiving SOD, There were no significant differences in
osmolar clearances among the groups.
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Table 1. Serum and urinary measurements in experimental animals
Abbreviations are: PA, aminonucleoside of puromycin; SOD, superoxide dismutase; CAT,
allopurinol.
Values are expressed as mean I s.
a P < 0.005 vs. control group.
bP < 0.001 vs. PA control group.
P < 0.05 vs. the PA control group.
P < 0.001 vs. all other groups.
P < 0.05 vs. all other groups.
normal in appearance or demonstrated less severe morphologic
changes (Fig. 3). Glomeruli from animals pretreated with al-
lopurinol had normal light microscopic features, with the ex-
ception of epithelial cell blebs (Fig. 3).
On electron microscopy, non-allopurinol treatment groups
exhibited glomerular epithelium with marked loss of foot pro-
cesses and epithelial cell spreading along the GBM, focal areas
of lifting of the epithelial cell from the GBM, cytoplasmic
vacuolization, and protein reabsorption droplets. The capillary
loops of the allopurinol-treated animals demonstrated the epi-
thelial cell spreading, vacuolization, and focal detachment of
the GEC from the GBM to a lesser extent on qualitative
evaluation.
Discussion
Fig. 2. Acute glomerular injury from the aminonucleoside ofpuromycin
in the rat. Light micrograph demonstrating epithelial cell blebs, seg-
mental area of mesangial cell proliferation, and matrix expansion with
obliteration of glomerular capillaries (arrow), and adhesions between
the glomerular tuft and Bowman's capsule (arrowheads). Toluidine
blue, x645
Morphologic studies
Light microscopy of thick sections from the renal cortex in
the PA control group showed that the vast majority of glomeruli
had segmental areas of mesangial cell proliferation and matrix
expansion, obliteration of glomerular capillaries, epithelial cell
blebbing, and adhesions of the glomerular tuft to Bowman's
capsule (Fig. 2). Contrasted to these marked changes in the PA
control group, glomeruli from SOD-treated animals were either
The role of oxygen free radicals in the aminonucleoside
model of nephrotic syndrome was explored because hypoxan-
thine, as an intermediary metabolite of PA (Fig. 1), can serve as
the substrate for superoxide anion production via the xanthine
oxidase system. In regard to the presence of xanthine oxidase in
renal tissue, Batelli, Corte, and Stirpe [17] detected enzyme
activity in homogenized samples of rat kidney. In models of
renal ischemia [18, 19], the protective effect of allopurinol, as
assessed by a marked diminution in the xanthine oxidase-
mediated oxidation of hypoxanthine [19], indirectly supports
the presence of this enzyme in the kidney. However, evidence
in the literature suggests that the form of the enzyme in vivo is
largely not the superoxide-producing oxidase (Type 0), but
rather an NAD-reducing dehydrogenase (Type D) [20]. It has
been demonstrated that proteolysis, acidosis, sulthydryl re-
agents, and anaerobic conditions convert the dehydrogenase
form (Type D) to the free radical-producing oxidase one (Type
0) [21, 22]. Thus, it would seem that in addition to an accumu-
lation of hypoxanthine from PA degradation, PA might also
have to be involved in the conversion of the Type D to Type 0
form by one of the above processes.
Condition
Body wt
g
Urine volume
ml/24 hr
Urinary protein
excretion rate
mg/24 hr
Serum
creatinine
mg/JOO ml
Urine
osmolality
mOsm/kg
Serum
osmolality
mOsm/kg
Osmolar
clearance
cc/day
PA 209 13.3 363.8 0.75 783.4 297.0 28.9(N = 5) 13.2 3.4 84.2 0.22 133.2 4.9 8.8
PA and SOD 198 5.0 l1l.0 0.54 l147.2c 292.7 19.9(N = 5) 6.6 0.8 41.7 0.10 81.9 6.1 2.5
PA and CAT 186 9.5 234.8 0.30 1053.2 288.6 31.2(N = 5) 2.4 2.4 61.1 0.10 131.2 2.9 6.1
PA and low-dose DMSO 210 11.4 378.6 0.53 823.6 296.0 30.6
(N = 5) 10.5 1.8 67.4 0.12 130.6 3.9 4.4
PA and high-dose DMSO 205 10.9 278.3 2.l2 772.5 314.0" 24.5(N = 8) 14.2 2.7 56.6 0.18 63.0 4.3 5.0
PA and ALLO 212 5.2 758b 0.33 1149.8 297.0 20.2(N = 5) 18.5 1.2 11.3 0.10 135.4 2.3 5.3
Saline 172 4.5 31.6
(N = 5) 5.8 1.1 6.9
catalase; DMSO, dimethyl sulfoxide; ALLO,
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Fig. 3. Histologic protection by allopurinol and superoxide dismutase. A Representative glomeruli from animals treated with aminonucleoside of
puromycin (PA). B Glomeruli from PA and superoxide dismutase group demonstrating less pronounced morphologic alterations. C Normal
glomeruli from the PA and allopurinol group with the exception of an occasional epithelial cell bleb. Toluidine blue, x370
The studies by Hoyer et a! [2, 3] show that the increased
proteinuria following administration of PA is the result of a
rapid and direct effect on the kidney. It was our hypothesis that
inhibition of oxygen free radical production or scavenging of
these toxic oxygen metabolites, at the time of PA delivery,
might protect the kidney. The histologic protection, on light
microscopy, and suppression of proteinuria conferred by a!-
lopurinol and SOD provides indirect evidence for a role of
oxygen free radicals in aminonucleoside nephrosis. However,
since electron microscopy still demonstrated the glomerular
epithelial cell changes typical for this model [4, 6] in allopurinol-
treated animals (albeit fewer capillary loops were involved), the
characteristic features of minimal change disease are not pre-
vented, but rather blunted by SOD and allopurinol. This also
corresponds with the significant decrement in urinary protein
excretion in the SOD- and allopurinol-treated animals rather
than a complete cessation of the proteinuria. On the other hand,
the more advanced histologic abnormalities of mesangial cell
proliferation and matrix expansion, collapse of glomerular
capillaries, and segmental adhesions may be prevented by
allopurinol and SOD. This is consistent with our suspicion that
minimal change disease and the advanced mesangial abnormal-
ities, which resemble certain features of focal and segmental
glomerulosclerosis (FSGS), may be two pathologic processes in
the same continuum of disease. The data would suggest that this
protection is mediated through the competitive inhibition of
xanthine oxidase by allopurinol, a hypoxanthine analog, and by
the reduction of the superoxide anion, catalyzed by SOD. The
effect of the latter agent would have to occur soon after its
delivery since the circulating hall-life of SOD is extremely
short, approximately 15 mm [13]. In fact, intravenously injected
SOD begins to accumulate in the kidneys of rats within 2 mm
[23]. Allopurinol, on the other hand, has a much longer half-life,
with its principal metabolite, alloxanthine, being excreted
slowly with a plasma half-time of 18 to 30 hr [241.
A role for toxic oxygen metabolites being responsible for
glomerular injury and consequent proteinuria in other experi-
mental nephritis models have recently been examined. In an
acute nephrotoxic nephritis model produced by infusion of
antiglomerular basement membrane antibody, treatment of
animals with catalase produced as much as 75% protection
against glomerular injury, whereas both SOD and DMSO were
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ineffective [25]. Similarly, the concomitant use of catalase
during intrarenal injection of phorbol mynstate acetate (PMA),
a potent activator of neutrophils resulting in free radical pro-
duction, prevented the development of proteinuria, whereas
SOD had no effect [26]. The efficacy of catalase supported the
hypothesis that hydrogen peroxide from activated neutrophils
rather than the superoxide anion or hydroxyl radical mediates
the glomerular injury [25]. The lack of effectiveness of catalase
and DMSO in our study does not exclude a role for hydrogen
peroxide and/or the hydroxyl free radical, respectively, nor
does it confirm the superoxide anion as the responsible toxic
oxygen metabolite. It has been suggested that the toxic oxygen
moiety may react with the administered oxygen free radical
scavenger, forming a secondary free radical which by itself can
produce injury [27]. This has been observed in the generation of
the methyl radical and methylperoxy radical after reaction of
the hydroxyl radical with DMSO [27].
The precise pathophysiologic defect accounting for the mas-
sive proteinuria in this model remains unexplained. Ryan and
Karnovsky [4] have shown that morphologically the GEC is the
primary target in aminonucleoside nephrosis. Recent in vitro
studies using GEC cultures exposed to PA have revealed
functional abnormalities which include a diminution of 14C-
glucosamine and 35S-sulfate incorporation into trichloroacetate-
precipitable substances secreted into the culture medium. In
addition, Kerjaschki et al [9, 10] have demonstrated that
defective glycosylation of the glomerular sialoprotein,
podocalyxin, may account for the loss of fixed negative charges
from the epithelial cell coat or cell surface, while Mynderse et
al [28] noted, using immunohistochemical means, a marked loss
of heparan sulfate proteoglycan in nephrotic rats treated with
PA. In contrast to these studies, Kanwar and Jakubowski [8]
have shown, using quantitative electron microscopic autoradi-
ography employing radiolabeled cationized ferritin, that there is
no loss in the density of the anionic sites of the GBM in
aminonucleoside nephrosis and the authors claim that the
proteinuria in this condition is not the result of the loss of
intrinsic GBM polyanion.
Clearly, additional in vitro studies will be needed to assess
the cytotoxic effect of oxygen free radicals on the GEC and
whether perturbations in the biosynthesis of proteoglycan and
sialoprotein by the GEC occur as a consequence of exposure to
these toxic oxygen metabolites. In addition, in vitro studies
using mesangial cell cultures may prove useful since the light
microscopic abnormalities of mesangial cell proliferation and
matrix expansion were prevented, in part, by SOD and more
completely by allopurinol.
Recently, workers have shown that orally administered
dipyridamole was effective in suppressing the protein excretion
in aminonucleoside nephrosis [29, 301. Nagase, Kumagin, and
Honda [30] ascribed the dipyridamole-induced suppression of
albuminuria to the preservation of the anionic charge of the
GBM by some unknown mechanism. An intriguing hypothesis
stems from the observation that dipyridamole is an inhibitor of
facilitated carrier-mediated adenosine transport [31]. Our labo-
ratory [5] has observed, in vitro, that GEC cultures incubated
with PA demonstrated increased 3H-adenosine cellular uptake,
suggesting that PA may increase the membrane permeability for
the intracellular flux of this nucleoside. This increased uptake of
adenosine in the presence of PA could serve as a mechanism to
provide the intracellular compartment with ample precursor for
hypoxanthine formation and subsequently for oxygen free
radical generation via xanthine oxidase. Earlier studies [32—35]
demonstrated inhibition of nephrosis by utilizing structural
analogs to PA, metabolites of PA, or adenosine, lending further
support to the hypothesis that PA may facilitate adenosine
transport into its target cell, the GEC.
The appearance of marked glomerular abnormalities on light
microscopy are clearly in contradistinction to earlier studies
demonstrating minimal change disease following PA adminis-
tration. Velosa et al [36] have produced a model of focal and
segmental glomeruloscierosis (FSGS) induced by repeated
intraperitoneal injections of PA in the rat. In that study, areas of
glomerular sclerosis corresponded to regions devoid of
polyanion, supporting their hypothesis that there was a close
relationship between irreversible epithelial cell damage and the
development of FSGS [36]. In our model, PA was administered
directly into the central venous circulation by rapid bolus
injection. Theoretically, the drug may have more reliably
achieved higher concentrations within the kidney compared
with previous studies in which the drug was administered by tail
vein. In fact, Den, Alexander, and Nagasawa [37] have shown
that there is an extremely rapid rate of urinary excretion of the
drug when given to clinically normal animals. Thus, higher
levels of PA within the glomerulus may have produced such
profound GEC injury that the animals developed marked
glomerular abnormalities, on light microscopy, 8 days following
the single PA injection.
In conclusion, we have demonstrated that allopurinol and
SOD protect the kidney against aminonucleoside nephrosis.
These results support the hypothesis that the associated gb-
merular lesion is mediated by oxygen free radicals generated via
xanthine oxidase. However, since allopurinol affects other
metabolic reactions (for example, inhibition of 5' nucleotidase)
[38], interference with other cellular processes cannot be ex-
cluded entirely.
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